Skin News and Research

RSS

US Appeals Court overturns ban on federal funding of embryonic stem cell research

The U.S. Federal Court of Appeals has overturned an August 2010 ban on federal funding of embryonic stem cell research, paving the way for broader exploration of how stem cells function and how they can be harnessed to treat a wide range of currently incurable diseases.

30 Apr 2011

Reimbursement policy influences choice of IMRT for treating breast cancer

What Medicare would pay for and where a radiation oncologist practiced were two factors that strongly influenced the choice of intensity-modulated radiation therapy (IMRT) for treating breast cancer, according to an article published April 29 online in the Journal of the National Cancer Institute. The use of IMRT and the cost of radiation therapy increased sharply over the period of the study.

29 Apr 2011

Scientists develop novel genetic model of premature aging disorders

Working with a group of national and international researchers, scientists from the Florida campus of The Scripps Research Institute have developed a new genetic model of premature aging disorders that could shed light on these rare conditions in humans and provide a novel platform for large-scale screening of compounds to combat these and other age-related diseases.

29 Apr 2011

New genetic study suspects Armadillos as source of leprosy in the U.S.

A new genetic study on leprosy bacteria reports that armadillos may be a source of infection in the Southern United States.

29 Apr 2011

UIC receives federal contract to develop antibiotics against three bacterial infections

Researchers at the University of Illinois at Chicago's Center for Pharmaceutical Biotechnology have been awarded a federal contract for up to $13.8 million to develop antibiotics to treat anthrax, tularemia and plague.

28 Apr 2011

LEO Pharma introduces new Taclonex website for plaque psoriasis treatment

LEO Pharma Inc., a wholly-owned US subsidiary of LEO Pharma A/S, makers of Taclonex brand products, today announced the launch of an enhanced and expanded website at www.taclonex.com.

28 Apr 2011

New microchip sensor can detect individual's respiratory rate

Researchers at Tyndall National Institute, UCC, Cork, have developed a microchip sensor that can detect a person's respiratory rate without any contact with the person under observation.

28 Apr 2011

Abnormal clock gene coordination observed in tissues of Alzheimer's patients

Twenty-four hour cycles, known as circadian rhythms, are important for proper body functions, including for normal brain function and mental health. Disruptions of circadian rhythms and sleep-wake cycles have been observed in patients with Alzheimer's disease. A new study by Douglas Institute researchers unravels a possible basis for these perturbations.

28 Apr 2011

Study examines racial differences between obesity and vitamin D among children

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that while black and white children with vitamin D deficiency both had higher fat levels, black children were more likely to have higher levels of fat just under their skin and white children were more likely to have higher levels of fat between their internal organs.

28 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Study finds prevalence of low vitamin D status among obese adolescents

A new study from Hasbro Children's Hospital has found that most obese adolescents are lacking in vitamin D.

28 Apr 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

ISC-4 topical compound may prevent skin cancer lesion formation

While incidents of melanoma continue to increase despite the use of sunscreen and skin screenings, a topical compound called ISC-4 may prevent melanoma lesion formation, according to Penn State College of Medicine researchers.

27 Apr 2011

VeraLight's Scout DS Device receives Health Canada License approval

VeraLight Inc., a privately held medical device company, based here, today announced its Scout DS Device was granted a Health Canada Medical Device Licence for non-invasive diabetes screening.

27 Apr 2011

Vitamin D levels may help explain racial disparities in hypertension

Lower vitamin D levels may explain part of the disparity in hypertension that exists between Black and White people in the US. High blood pressure is more common in Blacks than in Whites and persons with darker skin generally produce less vitamin D.

27 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

Durata attains global rights for dalbavancin to treat abSSSI

Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.

26 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

New discoveries in stem-cell technology

A scientist at the Gladstone Institutes has made two significant stem-cell discoveries that advance medicine and human health by creating powerful new approaches for using stem cells and stem-cell-like technology.

26 Apr 2011